Differences in Autonomic Nervous System Activity Between Long-acting Injectable Aripiprazole and Oral Aripiprazole in Schizophrenia

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2023 Mar 3

PMID 36869320

Authors

Saki Hattori

Akira Suda

Ikuko Kishida

Masatoshi Miyauchi

Yohko Shiraishi

Nobuhiko Noguchi

Taku Furuno

Takeshi Asami

Mami Fujibayashi

Natsuki Tsujita

Chie Ishii

Norio Ishii

Takashi Saeki

Tadashi Fukushima

Toshio Moritani

Yusuke Saigusa

Akitoyo Hishimoto

Affiliations

Soon will be listed here.

Abstract

Background: Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia. Long-acting injectable aripiprazole is a major treatment option for schizophrenia, but the effect of the aripiprazole formulation on ANS activity remains unclear. In this study, we compared ANS activity between oral aripiprazole and aripiprazole once-monthly (AOM) in schizophrenia.

Methods: Of the 122 patients with schizophrenia who participated in this study, 72 received oral aripiprazole and 50 received AOM as monotherapy. We used power spectral analysis of heart rate variability to assess ANS activity.

Results: Patients who received oral aripiprazole showed significantly diminished sympathetic nervous activity compared with those who received AOM. Multiple regression analysis revealed that the aripiprazole formulation significantly influenced sympathetic nervous activity.

Conclusion: Compared with oral aripiprazole, AOM appears to have fewer adverse effects, such as sympathetic nervous dysfunction.

References

Korell J, Green B, Rae A, Remmerie B, Vermeulen A . Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine. Eur J Clin Pharmacol. 2018; 74(5):593-599. DOI: 10.1007/s00228-018-2419-3. View

Xiao L, Zhao Q, Li A, Sun J, Wu B, Wang L . Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Psychopharmacology (Berl). 2022; 239(1):243-251. DOI: 10.1007/s00213-021-06044-x. View

Yoshimura R, Ueda N, Nakamura J . Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology. 2001; 44(3):129-33. DOI: 10.1159/000054932. View

Hart X, Hiemke C, Eichentopf L, Lense X, Clement H, Conca A . Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Psychopharmacology (Berl). 2022; 239(11):3377-3391. PMC: 9584998. DOI: 10.1007/s00213-022-06233-2. View

Tang C, Ramcharran D, Yang C, Chang C, Chuang P, Qiu H . A nationwide study of the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia in Taiwan. Schizophr Res. 2021; 237:9-19. DOI: 10.1016/j.schres.2021.08.015. View

Suda A, Hattori S, Kishida I, Miyauchi M, Shiraishi Y, Fujibayashi M . Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients. Neuropsychiatr Dis Treat. 2018; 14:2361-2366. PMC: 6149934. DOI: 10.2147/NDT.S173617. View

Olfson M, Gerhard T, Huang C, Crystal S, Stroup T . Premature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015; 72(12):1172-81. DOI: 10.1001/jamapsychiatry.2015.1737. View

Leucht C, Heres S, Kane J, Kissling W, Davis J, Leucht S . Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011; 127(1-3):83-92. DOI: 10.1016/j.schres.2010.11.020. View

Taipale H, Mehtala J, Tanskanen A, Tiihonen J . Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. Schizophr Bull. 2017; 44(6):1381-1387. PMC: 6192491. DOI: 10.1093/schbul/sbx176. View

10.

Chang H, Chang C, Tzeng N, Kuo T, Lu R, Huang S . Cardiac autonomic dysregulation in acute schizophrenia. Acta Neuropsychiatr. 2014; 25(3):155-64. DOI: 10.1111/acn.12014. View

11.

Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M . Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2012; 40(1):192-213. PMC: 3885289. DOI: 10.1093/schbul/sbs150. View

12.

Wang J, Liu Y, Zhu W, Zhang F, Zhou Z . Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis. Sci Rep. 2014; 4:7394. PMC: 4260225. DOI: 10.1038/srep07394. View

13.

Inada T, Inagaki A . Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015; 69(8):440-7. DOI: 10.1111/pcn.12275. View

14.

Fujibayashi M, Matsumoto T, Kishida I, Kimura T, Ishii C, Ishii N . Autonomic nervous system activity and psychiatric severity in schizophrenia. Psychiatry Clin Neurosci. 2009; 63(4):538-45. DOI: 10.1111/j.1440-1819.2009.01983.x. View

15.

Thayer J, Yamamoto S, Brosschot J . The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2009; 141(2):122-31. DOI: 10.1016/j.ijcard.2009.09.543. View

16.

Huang W, Chang L, Kuo T, Lin Y, Chen Y, Yang C . Impact of antipsychotics and anticholinergics on autonomic modulation in patients with schizophrenia. J Clin Psychopharmacol. 2013; 33(2):170-7. DOI: 10.1097/JCP.0b013e3182839052. View

17.

Hard M, Mills R, Sadler B, Turncliff R, Citrome L . Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. J Clin Psychopharmacol. 2017; 37(3):289-295. PMC: 5400404. DOI: 10.1097/JCP.0000000000000691. View

18.

Wakamatsu A, Aoki K, Sakiyama Y, Ohnishi T, Sugita M . Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics. Innov Clin Neurosci. 2013; 10(3):23-30. PMC: 3638848. View

19.

Birkhofer A, Geissendoerfer J, Alger P, Mueller A, Rentrop M, Strubel T . The deceleration capacity - a new measure of heart rate variability evaluated in patients with schizophrenia and antipsychotic treatment. Eur Psychiatry. 2011; 28(2):81-6. DOI: 10.1016/j.eurpsy.2011.06.010. View

20.

Kane J, Carson W, Saha A, McQuade R, Ingenito G, Zimbroff D . Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63(9):763-71. DOI: 10.4088/jcp.v63n0903. View